Free Trial

Elutia (ELUT) Competitors

Elutia logo
$2.27 +0.19 (+9.13%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$2.28 +0.00 (+0.22%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ELUT vs. TERN, HUMA, PRTA, HRTX, AMRN, PRME, SNDL, AQST, CTOR, and OLMA

Should you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Terns Pharmaceuticals (TERN), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Amarin (AMRN), Prime Medicine (PRME), SNDL (SNDL), Aquestive Therapeutics (AQST), Citius Oncology (CTOR), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry.

Elutia vs. Its Competitors

Terns Pharmaceuticals (NASDAQ:TERN) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Terns Pharmaceuticals had 1 more articles in the media than Elutia. MarketBeat recorded 3 mentions for Terns Pharmaceuticals and 2 mentions for Elutia. Elutia's average media sentiment score of 0.30 beat Terns Pharmaceuticals' score of -0.50 indicating that Elutia is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Terns Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Elutia
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Terns Pharmaceuticals currently has a consensus price target of $15.63, suggesting a potential upside of 244.92%. Elutia has a consensus price target of $8.00, suggesting a potential upside of 252.42%. Given Elutia's stronger consensus rating and higher possible upside, analysts clearly believe Elutia is more favorable than Terns Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Terns Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Elutia
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Terns Pharmaceuticals has a net margin of 0.00% compared to Elutia's net margin of -168.23%. Elutia's return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Terns PharmaceuticalsN/A -28.81% -27.55%
Elutia -168.23%N/A -96.70%

Terns Pharmaceuticals has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, Elutia has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Elutia has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/A-$88.85M-$1.09-4.16
Elutia$24.38M3.83-$53.95M-$1.93-1.18

Summary

Elutia beats Terns Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Elutia News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELUT vs. The Competition

MetricElutiaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$85.52M$2.87B$5.50B$8.95B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-1.1820.8026.9720.11
Price / Sales3.83286.31425.92119.81
Price / CashN/A41.1936.8257.86
Price / Book-1.737.487.985.56
Net Income-$53.95M-$55.04M$3.16B$248.40M
7 Day Performance5.09%2.44%2.36%4.67%
1 Month Performance20.11%1.90%2.15%6.64%
1 Year Performance-51.29%4.35%33.78%21.31%

Elutia Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELUT
Elutia
3.5801 of 5 stars
$2.27
+9.1%
$8.00
+252.4%
-53.0%$85.52M$24.38M-1.18180
TERN
Terns Pharmaceuticals
3.7045 of 5 stars
$3.73
-2.6%
$15.63
+318.9%
-39.8%$334.50MN/A-3.4240
HUMA
Humacyte
2.749 of 5 stars
$2.09
-1.4%
$11.71
+460.5%
-54.7%$328.85M$1.57M-3.03150News Coverage
Gap Up
PRTA
Prothena
3.0445 of 5 stars
$6.07
-0.2%
$31.50
+418.9%
-67.7%$327.27M$135.16M-2.92130
HRTX
Heron Therapeutics
3.8245 of 5 stars
$2.07
-3.3%
$5.00
+141.5%
-25.9%$326.49M$144.29M-34.50300Positive News
AMRN
Amarin
0.6044 of 5 stars
$16.22
+3.2%
$12.00
-26.0%
+13.8%$325.31M$228.61M-4.46360High Trading Volume
PRME
Prime Medicine
4.0534 of 5 stars
$2.47
+2.1%
$10.08
+308.2%
-25.3%$324.30M$3.85M-1.20234Options Volume
High Trading Volume
SNDL
SNDL
3.513 of 5 stars
$1.21
-1.6%
$3.63
+199.6%
-29.9%$323.21M$671.81M-4.172,516
AQST
Aquestive Therapeutics
1.2446 of 5 stars
$3.31
+1.8%
$10.14
+206.4%
+53.3%$322.82M$57.56M-5.61160
CTOR
Citius Oncology
0.3975 of 5 stars
$4.35
-3.3%
$3.00
-31.0%
N/A$321.99MN/A0.00N/A
OLMA
Olema Pharmaceuticals
1.726 of 5 stars
$4.26
-7.8%
$24.50
+475.1%
-58.0%$316.11MN/A-2.1270Positive News

Related Companies and Tools


This page (NASDAQ:ELUT) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners